A clean RS divergence into VWAP/ORH/ORL often gives tight-risk rotations
If you want a broader primer on how this pathway works, our guide to GLP-1 treatment is a helpful next read
Recent work has also identified the source of DPP-4 critical to GLP-1 and GIP degradation as being endothelial cells, rather than enteric epithelial or haematopoietic cells [19]
There may be a role for microdosing in certain scenarios, such as when side effects are not manageable or intolerable for patients, even at the lowest introductory dose
however, the progression from low-grade PanINs to PDAC involves sustained proliferation leading to the accumulation of somatic mutations and typically spans for longer than a decade 20,31
Deacon CF, Johnsen AH, Holst JJ (1995) Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo